Skip to product information
1 of 1

MULTI SCIENCES

Human IL-33 Antibody ELISA Kit

Human IL-33 Antibody ELISA Kit

SKU:EK133

Regular price Send Inquiry
Regular price Sale price Send Inquiry
Sale Sold out
View full details

Product Details

Human IL-33 Antibody ELISA Kit

Factory Name

MultiSciences

CatNum

EK133

Product Name

Human IL-33 ELISA Kit

Customs Name

Human IL-33 ELISA Kit

Product Spec

96T

Application

ELISA

Reactivity

Human

SDS

SDS - EK133

Assay Type

Sandwich ELISA

Suitable Sample Type

serum, plasma, cell culture supernates

Format

96-well strip plate

Storage

4℃ (unopened)standard stored at -20℃, others stored at 4℃ (opened)

Shipping Condition

4℃

Sample Volume

50 μl

Sensitivity

2.17 pg/ml

Standard Curve Range

31.25 - 2000 pg/ml

Spike Recovery Range

80% - 116%

Mean Spike Recovery

0.93

CV of Intra plate

3.8% - 4.5%

CV of Inter plate

1.5% - 2.9%

Components

96-well polystyrene microplate coated with a monoclonal antibody against IL-33
Human IL-33 Standard, lyophilized
IL-33 Detect Antibody
Standard Diluent
Streptavidin-HRP
Assay Buffer (10×)
Substrate (TMB)
Stop Solution
washing Buffer (20×)
Plate Covers

Describtion

This assay employs the quantitative sandwich enzyme immunoassay technique for the quantitative detection ofhuman IL-33. The Human IL-33 ELISA is for research use only. Not for diagnostic or therapeutic procedures.
Interleukin 33 (IL-33), also known as NF-HEV and DVS 27, is a 30-kDa member of the IL-1 family produced by a wide variety of cell types, including fibroblasts, mast cells, dendritic cells, macrophages, osteoblasts, endothelial cells, and epithelial cells. IL-33 induces helper T cells, mast cells, eosinophils and basophils to produce type 2 cytokines. IL-33 mediates its biological effects by interacting with the receptors ST2 and IL-1 Receptor Accessory Protein (IL1RAP), activating intracellular molecules in the NF-κB and MAP kinase signaling pathways that drive production of type 2 cytokines (e.g. IL-5 and IL-13) from polarized Th2 cells. The induction of type 2 cytokines by IL-33 in vivo is believed to induce the severe pathological changes observed in mucosal organs following administration of IL-33.